Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of MEDP is 514 and suggests 13% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Buy
Sell